Please login to the form below

Not currently logged in
Email:
Password:

Tourette's syndrome

This page shows the latest Tourette's syndrome news and features for those working in and with pharma, biotech and healthcare.

Neurocrine bags FDA approval for first tardive dyskinesia drug

Neurocrine bags FDA approval for first tardive dyskinesia drug

Neurocrine says it is also expecting to report results for a trial of valbenazine in children with Tourette's syndrome next month, although an earlier study in adults failed to show ... If positive, Neurocrine is hoping to start a phase III trial in

Latest news

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    Teva needs that kind of return, having forked out $3.5bn for SD-809's developer Auspex Pharma in 2015. ... Both companies are also exploring the use of their respective drugs to prevent tics associated with Tourette's syndrome.

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    Teva has been knocked back by an FDA decision not to approve deutetrabenazine, its candidate drug for chorea associated with Huntington's disease. ... and tics associated with Tourette's syndrome.

  • Neurocrine plans movement disorder drug filing in 2016 Neurocrine plans movement disorder drug filing in 2016

    Analysts at Nomura recently predicted that NBI-98854 could eventually become a $1.5bn product, even without a possible follow-up indication in Tourette's syndrome - and the announcement of the ... Neurocrine expects to complete its first phase Ib trial

  • Teva drug shows promise in movement disorder Teva drug shows promise in movement disorder

    in the US," said the trial's principal investigator Hubert Fernandez of the Cleveland Clinic. ... It also has late-stage trials ongoing in chorea associated with Tourette's syndrome. .

  • FDA starts review of Lundbeck’s antipsychotic aripiprazole

    This slow-down is expected to continue following the loss of patent protection on Eli Lilly's big-selling Zyprexa (olanzapine) brand earlier this year in the US. ... Otsuka is also developing a once-weekly oral formulation of aripiprazole which recently

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics